Skip to content

Institut de Formation Continue, Sciences et Médecine

Active
Non-profit associationfounded 2003active for 23 yearsHoogstraat 322, 1000 Brussel, Belgium78 active companies are registered at this addressKBO/BCE: BE 0860.682.978
Summary

Institut de Formation Continue, Sciences et Médecine has been active since 2003 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €468,420 and a net result of €37,608. Equity is shrinking by about 2.5% per year across the filed financial years. Its solvency ranks better than 72% of 1,162 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow ReportCompare
Institut de Formation Continue, Sciences et MédecineActiveChecked score 96/100
Risk analysis ReportCompare

Overview

Activity
Organisation of conventions and trade shows
NACE 82300Vocational training NACE 85592
1 site
Size
€648,914total assets 2025
Staff
5 FTE
Equity
€468,420
Surplus
€37,608
Financial health
96 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Structure
Board
6 members
2025 accounts 60 days early3 of 13 deeds summarised
Why 96lowers riskLegal form: non-profit associationLiquidity: current ratio 8.21, cash €526,613Equity €468,420 (72.2% of total assets)Founded in 2003Show the evidence

Checked score

Score 2025
96 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 67% of its sector peers (NACE 82, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 97=
equity 72.2% of total assets
Liquidity 99=
short-term debt 12.2% · cash 81.2%
Profitability 76-5
return on assets 5.8%
Bankruptcy probability, 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (12,652 companies, NACE 82, micro)
Last 24 months 11-2024: < 0.1%highest value 12-2024: < 0.1%● unchanged vs 11-2024highest value 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026lowest value 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026
Credit of up to €40,000 on 30-day terms is acceptable
Liquidity ample (current ratio 8.21, compared with 8.58 in 2024, above the usual 1.5; short-term debt: 12.2% and cash: 81.2% of total assets), and 27.8% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, micro): better than 72% on solvency, 93% on liquidity, 47% on profitability and 54% on growth.

The bankruptcy probability was computed on 27-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskneutral
lowers risk · Legal form: non-profit association
KBO
lowers risk · Liquidity: current ratio 8.21, cash €526,613
NBB · annual accounts
lowers risk · Equity €468,420 (72.2% of total assets)
NBB · annual accounts
lowers risk · Founded in 2003
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €468,420
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-06-2026, 60 days ahead of the deadline.
NBB · 9 filings
Deviation from the deadline
2025
60 days early
2024
72 days early
2023
54 days early
2022
48 days early
2021
24 days late
2020
31 days early
2019
3 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 35 days before the deadline; the sector median (NACE 82) for financial year 2024 is 7 days before the deadline, and 35% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 8 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
28-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Reappointments: Pierre Mols, Diane de Longueville…Gazette deed
  3. Annual accounts filedfinancial year 2024 · full…

Key points

  • Positive: Filed on time since financial year 2022accounts within the deadline every year 4 years View
  • Board6 directors in office 6 View
  • Total assets 20256 financial years filed €648,914 View

By topic

Financials

Financial year
2025
Total assets
€648,914
Profit
€37,608
Solvency
72.2%
Total assets▲ 8.0%
Net result
20182025
Go to Financials

Board & ownership

Board
6 members
  • Pierre MolsChair
  • Diane de LonguevilleDirector
  • Magali BartiauxDirector
  • Stefano MalinverniDirector
  • Victor TejedaDirector

and 1 other director

Go to Board & ownership

Timeline

Events
15
Since
2018
Next accounts
by 31-07-2027
  1. 31-12-2024Back to profit
  2. 07-06-2024Annual accounts filed
  3. 08-12-2023Appointments: MOLS Pierre, de LONGUEVILLE Diane and…
Go to Timeline

Company details

Sites
1
Legal form
Non-profit association
Activity
Organisation of conventions and trade showsNACE 82300
Founded
24-09-2003
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
59
Purpose
“A cette fin l’association pourra organiser tous congrès,séminaires,et autres…” (deed in French)
Go to Articles of association

Key facts about Institut de Formation Continue, Sciences et Médecine

What is the company number of Institut de Formation Continue, Sciences et Médecine?
0860.682.978. In Belgium the VAT number is the company number with BE in front: BE 0860.682.978.
Where is Institut de Formation Continue, Sciences et Médecine based?
The registered office is at Hoogstraat 322, 1000 Brussel.Company details
What does Institut de Formation Continue, Sciences et Médecine do?
According to the KBO register, the main activity is organisation of conventions and trade shows (NACE 82300).
What is the legal form of Institut de Formation Continue, Sciences et Médecine?
Non-profit association (VZW).
When was Institut de Formation Continue, Sciences et Médecine founded?
On 24-09-2003.
Is Institut de Formation Continue, Sciences et Médecine still active?
Yes, Institut de Formation Continue, Sciences et Médecine is an active enterprise in the KBO register.
How many employees does Institut de Formation Continue, Sciences et Médecine have?
On average 5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Institut de Formation Continue, Sciences et Médecine?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is Institut de Formation Continue, Sciences et Médecine profitable?
In financial year 2025, Institut de Formation Continue, Sciences et Médecine made a profit of €37,608.
Where can I find the annual accounts of Institut de Formation Continue, Sciences et Médecine?
Institut de Formation Continue, Sciences et Médecine filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Institut de Formation Continue, Sciences et Médecine due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to Institut de Formation Continue, Sciences et Médecine

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure